GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2010

FDA Rubber-Stamps APP Pharma’s Generic Topotecan for Small Cell Lung and Cervical Cancers

  • APP Pharmaceuticals reported FDA approval of its generic injectable topotecan anticancer drug. The Fresenius Kabi Pharmaceuticals subsidiary said it plans to launch the drug immediately. Topotecan for injection is indicated for the treatment of small cell lung cancer after failure of first-line chemotherapy, and for use in combination with cisplatin for stage IV-B and recurrent/persistent cervical cancer that is not curable using surgery and/or radiation therapy.

    APP’s topotecan is one of a growing number of generics that are competing directly with GSK’s topotecan drug Hycamtin®, which achieved global sales of £115 million in the first nine months of 2010, down 9% on the equivalent period in 2009. “As one of the first generic entries into the market, APP’s Topotecan for Injection will help reduce the cost of cancer treatment for patients who suffer from cervical and small cell lung cancers,” claims John Ducker, president and CEO at APP.

    APP’s topotecan is not the first generic version of Hycamtin to hit the market, however. Teva Pharma’s Topotecan Teva was first authorized in the EU in 1996. Just last month the European Medicines Agency also recommended approving Actavis Group’s generic topotecan, Potactasol.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »